---
title: "PTC Therapeutics authorizes $500 million buyback with no timetable or minimum"
url: "https://aibio.space/news/ptc-therapeutics-authorizes-500-million-buyback-no-timetable/"
event_date: "2026-11-03"
date_published: "2026-11-05"
description: "The board's authority is large next to PTC's $2,127.9 million in cash and investments, which include convertible note proceeds, while its Evrysdi royalties already go to Royalty Pharma. Nothing obliges PTC to buy a single share."
---

# PTC Therapeutics authorizes $500 million buyback with no timetable or minimum

PTC Therapeutics said on November 3 that its board had authorized the company to repurchase up to $500 million of its common stock. Chief Executive Officer Matthew B. Klein, M.D., said the program reflects "deep conviction in the strength of the Company and the prospects for near- and long-term growth." The authorization is large next to the $2,127.9 million in cash, cash equivalents and marketable securities PTC reported at September 30. It also commits PTC to nothing. Purchases are at management's discretion and subject to market conditions, and neither the filing nor the release sets a minimum amount, a timetable or an end date. Against that, Sephience sales are growing quickly, and Klein said on October 29 that PTC was on track for its cash flow breakeven milestone this year. [Buyback release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-ex99d1.htm) · [Buyback Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-20261103x8k.htm) · [Third quarter release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)

PTC may buy shares in the open market, including through pre-set trading plans, in privately negotiated transactions, through accelerated share repurchases or by other methods. The filing names no bank, broker or advisor and no counterparty for an accelerated repurchase. Chief Financial Officer Pierre Gravier signed the report. PTC said it would disclose any purchases in its quarterly and annual reports, so shareholders will not see the pace of buying until those filings arrive. [Buyback Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-20261103x8k.htm)

## How much of the cash is borrowed or already spoken for

Cash rose from $1,945.4 million at December 31, and debt helped. In June PTC issued $550.0 million of convertible senior notes due 2031. They pay no regular interest and convert at about $107.48 a share, and net proceeds came to approximately $535.4 million. PTC used approximately $328.8 million of that to repurchase $222.0 million of principal of its 2026 convertible notes. When $55.5 million of the remaining 2026 notes converted in September, PTC paid $74.8 million in cash. The company booked a $19.3 million loss on extinguishment of debt. If PTC undergoes a fundamental change, holders of the 2031 notes can demand repayment in cash at 100% of principal. [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm)

PTC's royalty income is also committed. Royalty Pharma has provided funding totaling $2.1 billion, and in exchange PTC sold it 100% of its rights to royalties on Roche's Evrysdi. The $81.7 million of Evrysdi royalty revenue in the third quarter therefore counts as revenue on PTC's books while the cash goes to Royalty Pharma. The resulting liability for sale of future royalties, PTC's largest, exceeds its cash and investments, though it is paid down with those royalties rather than with PTC's cash. PTC reported a stockholders' deficit at September 30. [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm) · [Third quarter release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)

The operating business has produced little cash so far this year. Operating activities provided $44.8 million in the nine months to September 30. The quarterly report attributes that mainly to the $50.0 million Novartis paid when the first Phase 3 trial of votoplam began. Sephience's sales growth also triggered milestone payments of $30.0 million and $50.0 million to the former Censa securityholders. PTC reported a third quarter net loss of $51.7 million, against net income of $15.9 million a year earlier. The loss included $111.0 million for the ST-920 Fabry disease gene therapy bought from Sangamo Therapeutics, with up to $100.0 million more due on regulatory milestones. [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm) · [Third quarter release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)

## What the buyback competes with

The strongest support for the buyback is sales. Third quarter net product and royalty revenue was $357.6 million, including $275.9 million of product revenue. Sephience, approved by the FDA in July 2025 for PKU, brought in $181.9 million. The older products look less steady. Translarna sales of $48.5 million included a government purchase order from Russia, and Emflaza fell to $25.1 million from $35.2 million. PTC raised its full-year product revenue guidance to $960 to $990 million. [Third quarter release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm) · [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm)

The pipeline still needs money and FDA decisions. PTC expects to complete a rolling application for accelerated approval of ST-920 in the fourth quarter of 2026, and says a launch could follow in 2027. A Type C meeting with the FDA on votoplam in Huntington's disease has slipped to the first quarter of 2027 because of FDA scheduling. For vatiquinone in Friedreich's ataxia, the FDA said in August 2025 that substantial evidence of efficacy was not demonstrated. PTC has started a new open label study of approximately 120 patients, compared against a matched natural history control. It guides to GAAP R&D and SG&A expense of $775 to $815 million this year. Klein said PTC keeps the flexibility to "pursue potential value creative business development transactions," but cash spent on stock is not available for those deals or for the pipeline. [Third quarter release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm) · [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm) · [Buyback release](https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-ex99d1.htm)

PTC had 83,544,284 shares outstanding on October 27, 2026, up from 81,474,366 at the end of 2025, mainly after option exercises and stock awards. Part of any buying may simply offset that dilution. The quarterly report says product sales, Novartis milestones and existing cash should fund operations for at least the next twelve months. The next quarterly or annual report will show whether PTC has started using the authority, and at what price. [Quarterly report](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-ex99d1.htm
- https://www.sec.gov/Archives/edgar/data/1070081/000110465926121713/tmb-20261103x8k.htm
- https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm
- https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm
